Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | CASP3 | P42574 | 2/20 | 0.43 |
| ▸ | FABP7 | O15540 | 1/20 | 0.41 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.41 |
| ▸ | MDM4 | O15151 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | TLR2 | O60603 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12703680 | 0.86 | KMT2A (0.55) | KMT2AEPHX2CASP3MDM4TP53 | |
| SCHEMBL31396078 | 0.83 | KMT2A (0.43) | KMT2AEPHX2CASP3FABP7FABP5 | |
| SCHEMBL18981796 | 0.83 | KMT2A (0.43) | KMT2AEPHX2CASP3FABP7FABP5 | |
| SCHEMBL38662522 | 0.82 | TLR2 (0.62) | KMT2ACASP3MDM4TP53TLR2 | |
| SCHEMBL27442611 | 0.82 | TLR2 (0.62) | KMT2ACASP3MDM4TP53TLR2 | |
| SCHEMBL3890833 | 0.82 | KMT2A (0.45) | KMT2AEPHX2CASP3TLR2 | |
| SCHEMBL892881 | 0.82 | KMT2A (0.46) | KMT2AEPHX2CASP3FABP7FABP5 | |
| SCHEMBL13984381 | 0.82 | MDM4 (0.48) | KMT2AEPHX2CASP3MDM4TP53 | |
| SCHEMBL13010967 | 0.82 | MDM4 (0.48) | KMT2AEPHX2CASP3MDM4TP53 | |
| SCHEMBL17830013 | 0.82 | MDM4 (0.48) | KMT2AEPHX2CASP3MDM4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8778613-B2 | Affinity resin | REVERSE PROTEOMICS RESEARCH INSTITUTE CO., LTD. (JP) | 2014-07-15 | — | — | US | disclosed |
| US-8778613-B2 | Affinity resin | REVERSE PROTEOMICS RESEARCH INSTITUTE CO., LTD. (JP) | 2014-07-15 | — | — | US | disclosed |
| US-8778613-B2 | Affinity resin | REVERSE PROTEOMICS RESEARCH INSTITUTE CO., LTD. (JP) | 2014-07-15 | — | — | US | disclosed |
| US-7919653-B2 | Method of inhibiting nonspecific interaction between molecules on solid phase support | REVERSE PROTEOMICS RESEARCH INSTITUTE CO., LTD. (JP) | 2011-04-05 | — | — | US | disclosed |
| US-7919653-B2 | Method of inhibiting nonspecific interaction between molecules on solid phase support | REVERSE PROTEOMICS RESEARCH INSTITUTE CO., LTD. (JP) | 2011-04-05 | — | — | US | disclosed |
| US-7919653-B2 | Method of inhibiting nonspecific interaction between molecules on solid phase support | REVERSE PROTEOMICS RESEARCH INSTITUTE CO., LTD. (JP) | 2011-04-05 | — | — | US | disclosed |
| EP-2157429-A2 | Method of inhibiting nonspecific interaction between molecules on solid phase support | Reverse Proteomics Research Institute Co., Ltd (JP) | 2010-02-24 | — | — | EP | disclosed |
| EP-2110393-A1 | Affinity resin | Reverse Proteomics Research Institute Co., Ltd (JP) | 2009-10-21 | — | — | EP | disclosed |
| US-20070167594-A1 | Affinity resin | REVERSE PROTEOMICS RESEARCH INSTITUTE CO., LTD (JP) | 2007-07-19 | — | — | US | disclosed |
| US-20070167594-A1 | Affinity resin | REVERSE PROTEOMICS RESEARCH INSTITUTE CO., LTD (JP) | 2007-07-19 | — | — | US | disclosed |
| US-20060177943-A1 | Method of inhibiting nonspecific interaction between molecules on solid phase support | REVERSE PROTEOMICS RESEARCH INSTITUTE CO., LTD. (JP) | 2006-08-10 | — | — | US | disclosed |
| EP-1674486-A1 | AFFINITY RESIN | Reverse Proteomics Research Institute Co., Ltd (JP) | 2006-06-28 | — | — | EP | disclosed |
| EP-1553412-A1 | METHOD OF INHIBITING NONSPECIFIC INTERACTION BETWEEN MOLECULES ON SOLID PHASE SUPPORT | Reverse Proteomics Research Institute Co., Ltd (JP) | 2005-07-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167594-A1 | Affinity resin | FCGR2A, FCGR1A, CD14 | KMT2A 887/4885EPHX2 2747/4885CASP3 4877/4885 |
| US-20060177943-A1 | Method of inhibiting nonspecific interaction between molecules on solid phase support | CD2BP2, CD14, SPR | KMT2A 3769/4885EPHX2 2680/4885CASP3 4883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.